Myriad sues BioReference Laboratories alleging BRCA cancer test patent violation

Myriad Genetics ($MYGN) is suing a third company for allegedly violating patents for its signature predictive cancer diagnostic test. This time, the Utah company is targeting New Jersey's BioReference Laboratories ($BRLI), which disclosed that it had been expecting legal action because of a Supreme Court decision that invalidated some Myriad patents but upheld others, opening the door to competition. Specifically, Myriad is going after BioReference's gene-sequencing laboratory GeneDx, because it began offering a test in August for inherited cancers including mutations involving BRCA1 and BRCA2 genes, which are the basis for Myriad's signature test. Myriad filed its lawsuit in the U.S. District Court in Utah. Myriad is already suing Gene By Gene and Ambry Genetics in similar complaints filed after each company launched separate tests relying on BRCA1 and BRCA 2 genes. Both companies have countersued, alleging violation of federal antitrust laws. Story

Sponsored By Paraza Pharma

Choosing the Right Pre-Clinical Collaborative Research Organization (CRO)

Learn about the key factors that are essential to creating a collaborative and productive working relationship to advance pre-clinical drug discovery programs.